JOSEPH GARCIA-PRATS to Double-Blind Method
This is a "connection" page, showing publications JOSEPH GARCIA-PRATS has written about Double-Blind Method.
Connection Strength
0.032
-
Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother. 2009 Jul; 53(7):2879-86.
Score: 0.015
-
Double-blind evaluation of developmental and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo. J Pediatr. 1995 May; 126(5 Pt 2):S33-42.
Score: 0.006
-
Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr. 1990 Dec; 117(6):947-53.
Score: 0.004
-
Evaluation of an intravenous immunoglobulin preparation for the prevention of viral infection among hospitalized low birth weight infants. Pediatr Infect Dis J. 1990 Jul; 9(7):470-5.
Score: 0.004
-
Retrolental fibroplasia: efficacy of vitamin E in a double-blind clinical study of preterm infants. N Engl J Med. 1981 Dec 03; 305(23):1365-71.
Score: 0.002